Expression of matrix metalloproteinases and their tissue inhibitors in the vein wall following superficial venous thrombosis

doi:10.3877/cma.j.issn.1674-0793.2024.05.005

Abstract

Abstract:

Objective

To investigate the changes in expression of matrix metalloproteinases (MMPs) and the tissue inhibitor of metalloproteinases (TIMPs) from superficial venous thrombosis (SVT), varicose great saphenous veins (VGSVs), and great saphenous veins (GSVs).

Methods

In the venous walls of the three groups, the expression of MMP-2, MMP-9, TIMP-1, and TIMP-2 proteins, protein-positive expression ratios, mRNA expression, and protein expression were determined by immunohistochemistry, polymerase chain reaction, and Western blotting.

Results

The MMP-2, MMP-9, TIMP-1, and TIMP-2 protein-positive expression ratios, mRNA and protein expression in the SVT group were significantly higher than those in the VGSVs and the GSVs groups (P<0.05). The MMP-2/TIMP-2 ratios in the SVT and the VGSVs groups were significantly lower than those in the GSVs group (P<0.05), respectively. The MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in the SVT group were significantly lower than those in the VGSVs and the GSVs groups (P<0.05), respectively.

Conclusions

Disequilibrium of MMPs and TIMPs in SVT wall occurs due to underlying high hydrostatic pressure and inflammation. These results suggested that MMPs and TIMPs participate in the process of venous wall remodeling.

Key words: Superficial venous thrombosis, Saphenous vein, Matrix metalloproteinases, Tissue inhibitor of metalloproteinases

Xingyue Li, Wei Dong, Yongbo Xu, Wenfa Zhang, Xiaoxuan Hu, Yuxu Zhong, Haibo Chu. Expression of matrix metalloproteinases and their tissue inhibitors in the vein wall following superficial venous thrombosis[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 338-343.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2024.05.005

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2024/V18/I05/338

Figures/Tables 8

References 26

[1]	Zhai Y, Lu YM, Lu W, et al. Radiofrequency ablation of the great saphenous vein in the treatment of varicose veins of the lower extremities[J]. Ann Ital Chir, 2022, 93: 235-240.
[2]	Farah MH, Nayfeh T, Urtecho M, et al. A systematic review supporting the Society for Vascular Surgery, the American Venous Forum, and the American Vein and Lymphatic Society guidelines on the management of varicose veins[J]. J Vasc Surg Venous Lymphat Disord, 2022, 10(5): 1155-1171.
[3]	Stücker M. Superficial venous thrombosis, varicose veins, and chronic venous insufficiency: An update for clinical practice[J]. Inn Med (Heidelb), 2022, 63(6): 612-618.
[4]	Pich J. Treatment for superficial thrombophlebitis of the leg[J]. Br J Community Nurs, 2019, 24(6): 263-264.
[5]	Liu X, Liu D, Shen Y, et al. Matrix metalloproteinases in invertebrates[J]. Protein Pept Lett, 2020, 27(11): 1068-1081.
[6]	Jian FG, Chu HB, Liu G, et al. Morphological characteristics of the walls of thrombophlebitic saphenous vein[J]. Phlebology, 2014, 29(3): 164-170.
[7]	Naik B, Kumar M, Khanna AK, et al. Clinico-histopathological study of varicose vein and role of matrix metalloproteinases-1, matrix metalloproteinases-9 and tissue inhibitor of matrix metalloproteinase-1 in varicose vein formation[J]. Indian J Pathol Microbiol, 2016, 59(1): 25-30.
[8]	Chu HB, Yan F, Zhao JH, et al. Assessment of the infiltration of inflammatory cells in the walls of thrombotic varicose veins[J]. Angiology, 2013, 64(1): 69-72.
[9]	Humphrey JD. Mechanisms of vascular remodeling in hypertension[J]. Am J Hypertens, 2021, 34(5): 432-441.
[10]	Barallobre-Barreiro J, Oklu R, Lynch M, et al. Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins[J]. Cardiovasc Res, 2016, 110(3): 419-430.
[11]	Raffetto JD, Yu W, Wang X, et al. Sulodexide improves contraction and decreases matrix metalloproteinase-2 and -9 in veins under prolonged stretch[J]. J Cardiovasc Pharmacol, 2020, 75(3): 211-221.
[12]	Serralheiro P, Cairrão E, Maia CJ, et al. Effect of TGF-β1 on MMP/TIMP and TGF-β1 receptors in great saphenous veins and its significance on chronic venous insufficiency[J]. Phlebology, 2017, 32(5): 334-341.
[13]	Serra R, Grande R, Buffone G, et al. Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines[J]. Int Wound J, 2016, 13(1): 53-58.
[14]	Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases[J]. Int J Mol Sci, 2020, 21(24): 9739.
[15]	Simões G, Pereira T, Caseiro A. Matrix metaloproteinases in vascular pathology[J]. Microvasc Res, 2022, 143: 104398.
[16]	Malik J, Stulc T, Ceska R. Matrix metalloproteinases in isolated hypercholesterolemia[J]. Int Angiol, 2005, 24(3): 300-303.
[17]	Gresele P, Falcinell E, Sebastiano M, et al. Matrix metalloproteinases and platelet function[J]. Prog Mol Biol Transl Sci, 2017, 147: 133-165.
[18]	Lood C, Amisten S, Gullstrand B, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the typeⅠ interferon system is strongly associated with vascular disease[J]. Blood, 2010, 116(11): 1951-1957.
[19]	Zhang CY, Jiang G, Gao XL. Matrix metalloproteinase-responsive drug delivery systems[J]. Bioconjug Chem, 2023, 34(8): 1349-1365.
[20]	Xu YB, Bei YY, Li Y, et al. Phenotypic and functional transformation in smooth muscle cells derived from varicose veins[J]. J Vasc Surg Venous Lymphat Disord, 2017, 5(5): 723-733.
[21]	Gillespie DL, Patel A, Fileta B, et al. Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13[J]. J Surg Res, 2002, 106(2): 233-238.
[22]	Kowalewski R, Sobolewski K, Wolanska M, et al. Matrix metalloproteinases in the vein wall[J]. Int Angiol, 2004, 23(2): 164-169.
[23]	Reddy VS, Prabhu SD, Mummidi S, et al. Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation[J]. Am J Physiol Heart Circ Physiol, 2010, 299(4): H1242-H1254.
[24]	Xu GF, Ou L, Liu Y, et al. Upregulated expression of MMP family genes is associated with poor survival in patients with esophageal squamous cell carcinoma via regulation of proliferation and epithelial-mesenchymal transition[J]. Oncol Rep, 2020, 44(1): 29-42.
[25]	Serra R. Matrix metalloproteinases in health and disease[J]. Biomolecules, 2020, 10(8): 1138.
[26]	Méndez-Barbero N, Gutiérrez-Muñoz C, Blanco-Colio LM. Cellular crosstalk between endothelial and smooth muscle cells in vascular wall remodeling[J]. Int J Mol Sci, 2021, 22(14): 7284.

基因名称	基因编码	引物序列	产物大小(bp)
MMP-2	NM_001127891.1	上游引物：5'-ATCTTTGCTGGAGACAAATTCTGGA-3'	175
		下游引物：5'-GCTTCAGGTAATAGGCACCCTTGA-3'
MMP-9	NM_004994.2	上游引物：5'- ACGCACGACGTCTTCCAGTA -3'	94
		下游引物：5'- CCACCTGGTTCAACTCACTCC -3'
TIMP-1	NM_003254.2	上游引物：5'-CCTTATACCAGCGTTATGAGATCAA-3'	194
		下游引物：5'-AGTGATGTGCAAGAGTCCATCC-3'
TIMP-2	NM_003255.4	上游引物：5'-CTGGACGTTGGAGGAAAGAAGG-3'	148
		下游引物：5'-CCATCTGGTACCTGTGGTTCAGG-3'
GAPDH	NM_002046.3	上游引物：5'-GCACCGTCAAGGCTGAGAAC-3'	138
		下游引物：5'-TGGTGAAGACGCCAGTGGA-3'

基因名称	基因编码	引物序列	产物大小(bp)
MMP-2	NM_001127891.1	上游引物：5'-ATCTTTGCTGGAGACAAATTCTGGA-3'	175
		下游引物：5'-GCTTCAGGTAATAGGCACCCTTGA-3'
MMP-9	NM_004994.2	上游引物：5'- ACGCACGACGTCTTCCAGTA -3'	94
		下游引物：5'- CCACCTGGTTCAACTCACTCC -3'
TIMP-1	NM_003254.2	上游引物：5'-CCTTATACCAGCGTTATGAGATCAA-3'	194
		下游引物：5'-AGTGATGTGCAAGAGTCCATCC-3'
TIMP-2	NM_003255.4	上游引物：5'-CTGGACGTTGGAGGAAAGAAGG-3'	148
		下游引物：5'-CCATCTGGTACCTGTGGTTCAGG-3'
GAPDH	NM_002046.3	上游引物：5'-GCACCGTCAAGGCTGAGAAC-3'	138
		下游引物：5'-TGGTGAAGACGCCAGTGGA-3'

检测指标	SVT组	VGSVs组	GSVs组	F值	P值
MMP-2	70.040±4.257^a	52.000±3.189^b	5.933±2.375	335.864	<0.001
MMP-9	70.400±3.175^a	52.960±2.475^b	5.000±1.927	2888.871	<0.001
TIMP-1	71.920±3.752^a	52.880±2.744^b	5.000±2.299	1169.311	<0.001
TIMP-2	72.600±4.052^a	53.600±2.769^b	4.200±2.007	637.307	<0.001

检测指标	SVT组	VGSVs组	GSVs组	F值	P值
MMP-2	70.040±4.257^a	52.000±3.189^b	5.933±2.375	335.864	<0.001
MMP-9	70.400±3.175^a	52.960±2.475^b	5.000±1.927	2888.871	<0.001
TIMP-1	71.920±3.752^a	52.880±2.744^b	5.000±2.299	1169.311	<0.001
TIMP-2	72.600±4.052^a	53.600±2.769^b	4.200±2.007	637.307	<0.001

检测指标	SVT组	VGSVs组	GSVs组	F值	P值
MMP-2/TIMP-2	0.968±0.087^a	0.972±0.071^a	1.651±0.965	-40.137	<0.001
MMP-9/TIMP-1	0.982±0.080	1.005±0.077	1.176±0.741	-141.682	0.226

Please choose a citation manager

Content to export